BIIB Jan 2025 395.000 call
| Previous close | 1.2000 |
| Open | 1.2000 |
| Bid | 0.0000 |
| Ask | 4.4000 |
| Strike | 395.00 |
| Expiry date | 2025-01-17 |
| Day's range | 1.2000 - 1.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 224 |
Barrons.comHealthcare Stocks Have Popped. Consider These 2 That Haven’t.
Healthcare stocks have jumped into pricey territory. The exchange-traded fund, home to health insurers, pharmaceuticals and medical device makers, has gained 6% to $155 from a low point in early August. Money has poured into the sector as markets have grown concerned about the economy, particularly with growth slowing in retail and manufacturing.
Investor's Business DailyIs Eli Lilly Stock A Buy After Slashing The Price Of Its New Weight-Loss Drug?
Eli Lilly halved the price of a new version of its weight-loss drug, Zepbound. Is Eli Lilly stock a buy right now?
GlobeNewswireBiogen Board Appoints Two New Independent Directors
Dr. Lloyd Minor and Prof Sir Menelas Pangalos bring significant scientific expertise and considerable experience in medicine research and developmentCAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- The Biogen Inc. (Nasdaq: BIIB) Board of Directors (the “Board”) today announced the appointments of two new independent directors, Lloyd B. Minor, M.D., effective October 1, 2024, and Sir Menelas (Mene) Pangalos, Ph.D., effective January 1, 2025. Dr. Minor is currently the Dean of the Stanford Uni
